Ulcerative Colitis Market to Observe Stupendous Growth at a CAGR of 9.4% by 2032 – Estimates DelveInsight | Key Companies – AbbVie, Boehringer Ingelheim, Arena Pharma, Eli Lilly, Janssen

November 21 15:42 2022
Ulcerative Colitis Market to Observe Stupendous Growth at a CAGR of 9.4% by 2032 - Estimates DelveInsight | Key Companies -  AbbVie, Boehringer Ingelheim, Arena Pharma, Eli Lilly, Janssen
Delveinsight Business Research LLP
The dynamics of the Ulcerative Colitis market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending across the world, and the expected launch of emerging therapies

As per DelveInsight, among the 7MM, the highest market size of Ulcerative Colitis was accessed in the United States, followed by Germany, and the United Kingdom, in 2021.

DelveInsight’s “Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Ulcerative Colitis market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Ulcerative Colitis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Ulcerative Colitis Market

Ulcerative Colitis: An Overview

Ulcerative Colitis (UC) is a chronic and long-lasting disease that causes inflammation—irritation or swelling—and sores called ulcers on the inner lining of the large intestine. It is a chronic inflammatory disease of the gastrointestinal (GI) tract called inflammatory bowel disease (IBD). It most often begins gradually and can become worse over time. Symptoms can be mild to severe. Most people have periods of remission—times when symptoms disappear—that can last for weeks or years. The goal of care is to keep people in remission long-term.

The exact cause of Ulcerative Colitis is unknown. Researchers believe the following factors may play a role in causing ulcerative colitis: overactive intestinal immune system, genes, and environment.

Ulcerative Colitis Market Key Facts

  • The Ulcerative Colitis market size in the 7MM is expected to change during the study period 2019–2032 at a CAGR of 9.4%. According to the estimates, the highest market size of Ulcerative Colitis is accessed in the United States, followed by Germany, and the United Kingdom, in 2021.

  • In 2021, the overall Ulcerative Colitis prevalent cases were accessed to be around 2,221,400+ in the 7MM, which is expected to grow during the forecast period, i.e., 2022–2032.

  • In the United States, the total Ulcerative Colitis prevalent cases were around 1,017,400+ in the year 2021.

  • In the year 2021, the total prevalent cases of Ulcerative Colitis were around 1,020,600+ in EU-5.

  • Ulcerative colitis affects males and females in equal numbers. In the United States and Western Europe, the frequency (i.e., prevalence) of the disease is approximately 70 to 150 cases per 100,000 in the general population.

  • Some of the leading pharma and biotech giants in the Ulcerative Colitis Market include Janssen Pharmaceuticals, Takeda Pharmaceuticals, Pfizer, EA Pharma, Kissei Pharma, Gilead Sciences, Galapagos NV, Celgene (Bristol-Myers Squibb), AbbVie, Arena Pharmaceuticals, Reistone Biopharma, Landos Biopharma, Bridge Biotherapeutics, Applied Molecular Transport, AbGenomics (AltruBio), Abivax, Connect Biopharma, Boehringer Ingelheim, Eli Lilly and Company, InDex Pharmaceuticals, Bristol-Myers Squibb, Protagonist Therapeutics, Mesoblast Ltd, and others

Ulcerative Colitis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Ulcerative Colitis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Ulcerative Colitis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Ulcerative Colitis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

The Report Covers the Ulcerative Colitis (UC) Epidemiology Segmented by –

  • Total Prevalent Cases of Ulcerative Colitis 

  • Total Diagnosed Cases of Ulcerative Colitis

  • Severity-specific Cases of Ulcerative Colitis 

  • Age-specific Cases of Ulcerative Colitis 

  • Treated cases of Ulcerative Colitis

Ulcerative Colitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ulcerative Colitis market or expected to get launched during the study period. The analysis covers the Ulcerative Colitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ulcerative Colitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Ulcerative Colitis Market Will Evolve by 2032:


Ulcerative Colitis Therapeutics Analysis

Ulcerative Colitis treatment depends on the disease’s severity and symptoms. Each person experiences ulcerative colitis differently, so healthcare providers adjust treatments to improve the person’s symptoms and induce, or bring about, remission.

Key Companies in the Ulcerative Colitis Market include:

AbbVie, Arena Pharmaceuticals, DBV Technologies, Eli Lilly and Company, Galapagos, Genentech, Gilead Sciences, Immunic, Kaleido Biosciences, Landos Biopharma, Novartis Pharmaceuticals, Palobiofarma, Rebiotix, Roche, Salix Pharmaceuticals, Sanofi, Regeneron, Seres Therapeutics, Shire, Vedanta Biosciences, and many others.

Ulcerative Colitis Therapies covered in the report include:

  • Skyrizi (Risankizumab): AbbVie/Boehringer Ingelheim

  • Etrasimod (APD334): Arena Pharmaceuticals

  • Mirikizumab (LY-3074828): Eli Lilly and Company

  • Tremfya (Guselkumab): Janssen (Johnson & Johnson)

  • BT 11: Landos Biopharma

  • Deucravacitinib (BMS-986165): Bristol-Myers Squibb

  • SHR 0302: Reistone Biopharma

And many others.

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Ulcerative Colitis Competitive Intelligence Analysis

4. Ulcerative Colitis Market Overview at a Glance

5. Ulcerative Colitis Disease Background and Overview

6. Ulcerative Colitis Patient Journey

7. Ulcerative Colitis Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Ulcerative Colitis Treatment Algorithm, Current Treatment, and Medical Practices

9. Ulcerative Colitis Unmet Needs

10. Key Endpoints of Ulcerative Colitis Treatment

11. Ulcerative Colitis Marketed Products

12. Ulcerative Colitis Emerging Drugs and Latest Therapeutic Advances

13. Ulcerative Colitis Seven Major Market Analysis

14. Attribute Analysis

15. Ulcerative Colitis Market Outlook (In US, EU5, and Japan)

16. Ulcerative Colitis Access and Reimbursement Overview

17. KOL Views on the Ulcerative Colitis Market

18. Ulcerative Colitis Market Drivers

19. Ulcerative Colitis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


Other Trending Healthcare Reports By DelveInsight

Ulcerative Colitis (UC) Pipeline Insights

Ulcerative Colitis (UC)– Pipeline Insight, 2022” report provides comprehensive insights about 110+ companies and 110+ drugs in the Ulcerative Colitis (UC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/